|
Match
|
Document |
Document Title |
|
|
US20160136258 |
PHARMACEUTICAL COMPOSITION CONTAINING A STABILISED mRNA OPTIMISED FOR TRANSLATION IN ITS CODING REGIONS
The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilised by sequence modifications and optimised for translation. The pharmaceutical composition... |
|
|
US20100239608 |
PHARMACEUTICAL COMPOSITION CONTAINING A STABILISED mRNA OPTIMISED FOR TRANSLATION IN ITS CODING REGIONS
The present invention relates to a pharmaceutical composition containing an mRNA that is stabilised by sequence modifications in the translated region and is optimised for the translation. The... |
|
|
US20090104230 |
COMPOSITIONS AND METHODS OF USING CAPSID PROTEIN FROM FLAVIVIRUSES AND PESTIVIRUSES
This invention provides methods of inducing cell death with Flavivirus or Pestivirus capsid protein, such as West Nile virus (WNV) capsid protein, and functional fragments thereof. The invention... |
|
|
US20080311156 |
VACCINES
The present invention relates to adjuvant compositions which are suitable to be used in vaccines. In particular, the adjuvant compositions of the present invention comprises a saponin and an... |
|
|
US20070298053 |
Cattle reproductive disease vaccines
The present invention relates to combination vaccines and methods for treating or preventing diseases or disorders in an animal caused by infection by Bovine Viral Diarrhea Virus (BVDV) Types 1... |
|
|
US20140141070 |
LIPOSOMES HAVING USEFUL N:P RATIO FOR DELIVERY OF RNA MOLECULES
Nucleic acid immunisation is achieved by delivering a RNA encapsulated within a liposome comprising a cationic lipid, wherein the liposome and the RNA have a N:P ratio of between 1:1 and 20:1. |
|
|
US20120107355 |
METHOD OF RAPIDLY PRODUCING IMPROVED VACCINES FOR ANIMALS
A method of quickly producing a vaccine for a biotype of pathogenic microorganism is described, where a nucleic acid molecule or fragment thereof is obtained from a biological sample from an... |
|
|
US20110293723 |
SYNTHETIC NANOCARRIER COMBINATION VACCINES
Disclosed are dosage forms and related methods, that include a first population of synthetic nanocarriers that have one or more first antigens coupled to them, one or more second antigens that are... |
|
|
US20060159704 |
Use of flavivirus for the expression of protein epitopes and development of new live attenuated vaccine virus to immunize against flavivirus and other infectious agents
The present invention relates to a vaccine against infections caused by flavivirus. More particularly to the use of the YF vaccine virus (17D) to express at the level of its envelope, protein... |
|
|
US20050002968 |
Flavivirus vaccines
The invention provides attenuated flavivirus vaccines and methods of making and using these vaccines. |
|
|
US20100330121 |
RECOMBINANT ALPHAVIRUS-BASED VECTORS WITH REDUCED INHIBITION OF CELLULAR MACRO-MOLECULAR SYNTHESIS
Isolated nucleic acid molecules are disclosed, comprising an alphavirus nonstructural protein gene which, when operably incorporated into a recombinant alphavirus particle, eukaryotic layered... |
|
|
US20080026071 |
Microparticles for delivery of heterologous nucleic acids
Microparticles with adsorbent surfaces, methods of making such microparticles, and uses thereof, are disclosed. The microparticles comprise a polymer, such as a poly(α-hydroxy acid), a polyhydroxy... |
|
|
US20070231350 |
West Nile vaccine
The present invention provides a safe and effective vaccine composition against West Nile virus disease. An immunogenically active component of West Nile virus or plasmid DNA, an adjuvant such as... |
|
|
US20160120972 |
INACTIVATED DENGUE VIRUS VACCINE WITH ALUMINIUM-FREE ADJUVANT
The present disclosure provides immunogenic compositions for the prevention and/or treatment of disease caused by dengue virus. |
|
|
US20130028934 |
Stabilizer and Vaccine Composition Comprising One or More Live Attenuated Flaviviruses
The present invention relates to stabilizers for compositions, including immunogenic compositions, such as vaccine compositions, comprising one or more live attenuated flaviviruses, to bulk... |
|
|
US20100270202 |
Method of Immunization Against the 4 Dengue Serotypes
The invention relates to a method for inducing a protection against the 4 dengue serotypes in a patient, comprising (a) a first series of administrations (i) of a dose of a vaccinal dengue virus... |
|
|
US20070212376 |
Method of treating and preventing infectious diseases
The present invention relates to a method for reducing the occurrence and severity of infectious diseases, especially infectious diseases in which lipid-containing infectious organisms are found... |
|
|
US20090191240 |
Flavivirus Vaccines
The invention provides flavivirus vaccines and methods of making and using these vaccines. |
|
|
US20120244182 |
USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION
The invention provides immunostimulatory compositions and methods of administration thereof. Also provided are methods of administering a tryptanthrin compound in an effective amount to enhance... |
|
|
US20100047280 |
FLAVIVIRUS NS1 SUBUNIT VACCINE
The present invention relates to NS1 proteins or parts thereof of Flaviviruses, in particular of Dengue viruses useful for vaccination against said Flavivirus and against one or more other... |
|
|
US20090263470 |
Vaccine Compositions Comprising Virosomes and a Saponin Adjuvant
This invention provides virosome preparations from an enveloped virus, in particular from influenza virus, containing from said virus, and a saponin adjuvant. In particular the invention provides... |
|
|
US20140302091 |
METHODS AND COMPOSITIONS FOR LIVE ATTENUATED VIRUSES
Embodiments herein relate to compositions of and methods for live viruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live,... |
|
|
US20130115244 |
Immunogenic Substances Comprising a Polyinosinic Acid - Polycytidilic Acid Based Adjuvant
The present invention provides a polynucleotide adjuvant (PICKCa) composition and methods of use in eliciting an immune response, in particular a mucosal immune response. The polynucleotide... |
|
|
US20130095136 |
Tetravalent Dengue Vaccines
The invention provides tetravalent Dengue vaccines, and methods of using these vaccines to prevent or to treat Dengue infection. |
|
|
US20160102099 |
ANTI-VIRAL COMPOUNDS
Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells,... |
|
|
US20140112953 |
INACTIVATED DENGUE VIRUS VACCINE
The present invention provides formulations of an immunogenic composition containing a purified inactivated Dengue virus, and method for producing them. |
|
|
US20130323280 |
METHODS FOR PREPARING VESICLES AND FORMULATIONS PRODUCED THEREFROM
The present disclosure provides methods for preparing vesicles. In one aspect, the methods involve providing a molten mixture of vesicle-forming lipids and adding the molten mixture of... |
|
|
US20120114693 |
NUCLEIC ACID MUCOSAL IMMUNIZATION
Mucosal delivery of antigens using, for example, a replication-defective gene delivery vehicle, particularly replication-defective alphavirus vectors and particles, is described. Also described... |
|
|
US20100239612 |
Method of Immunization Against the 4 Serotypes of Dengue Fever
The invention relates to a method for inducing protection against the 4 serotypes of dengue fever in a patient, comprising: (a) the administration of a monovalent vaccine comprising a vaccinal... |
|
|
US20090246223 |
Inactivated Chimeric Vaccines and Related Methods of Use
Embodiments of the present invention generally provide an inactivated chimeric virus vaccine and/or immunogenic composition for the treatment or prevention of viral infection. Further, various... |
|
|
US20060204523 |
Flavivirus vaccine delivery system
A flaviviral expression vector, construct and system are provided that each comprise a flaviviral replicon that faciliates intracellular self-replication leading to high-level expression of RNA... |
|
|
US20110045024 |
RNA VIRUS VACCINES AND METHODS
The invention is a vaccine, and method of vaccination, against RNA viruses, including RNA viruses in the family Flaviviridae, which includes for example West Nile Virus, Yellow fever virus, Dengue... |
|
|
US20160122312 |
ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF
Disclosed herein are compounds, pharmaceutical compositions, and methods for the treatment of viral infection, including RNA viral infection, as well as compounds, pharmaceutical compositions, and... |
|
|
US20150265695 |
VACCINE COMPOSITIONS FOR PREVENTION AGAINST DENGUE VIRUS INFECTION
The present invention relates to vaccine compositions that are useful in a method of protecting a human subject against dengue disease. |
|
|
US20140314739 |
Vaccine adjuvant composition comprising inulin particles
The present invention provides a composition comprising or consisting of inulin particles for use in the reduction or inhibition of inflammation, and/or for treating or preventing inflammatory... |
|
|
US20140227321 |
ANTI-VIRAL COMPOUNDS
Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells,... |
|
|
US20110223197 |
Mucosal and Systemic Immunization with Alphavirus Replicon Particles
Mucosal and systemic administration of compositions comprising alphavirus replicon particles to induce immune responses in a subject is described. |
|
|
US20100221285 |
Method of Immunization Against the 4 Dengue Serotypes
The invention relates to a method for inducing a homologous protection against the 4 dengue serotypes in a patient, comprising the sequential administration, to said patient, (i) of a dose of a... |
|
|
US20090041852 |
DRY POWDER COMPOSITIONS AND SYSTEMS FOR POULTRY VACCINATION
This invention provides a dry powder composition for poultry vaccination via inhalation comprising an effective amount of a poultry vaccine agent, and a supporting amount of carriers for said... |
|
|
US20120021001 |
MARKED BOVINE VIRAL DIARRHEA VIRUS VACCINES
The present invention is directed to a bovine viral diarrhea virus comprising at least one helicase domain amino acid mutation wherein the mutation in the NS3 domain results in a loss of... |
|
|
US20100233209 |
Chikungunya virus infectious clones and uses therefor
The present invention developed and characterized in vitro and in vivo three full-length cDNA clones based on the alphavirus chikungunya, two sets of infectious clones based on CHIKV and replicons... |
|
|
US20080171002 |
Products For Receptor Mediated Activation And Maturation Of Monocyte-Derived Dendritic Cells By A Phosphorylated Glucomannane Polysaccharide
Phosphorylated glucomannan polysaccharide compositions are shown to effectively enhance healthy immune function. Dosage forms including pills, sprays, functional foods and cosmetics may achieve... |
|
|
US20120003277 |
NANOEMULSION VACCINES
The present invention provides methods and compositions for the stimulation of immune responses. Specifically, the present invention provides nanoemulsion compositions harboring one or more... |
|
|
US20070185025 |
Filoviral immunosuppressive peptides and uses thereof
The invention provides a region of strong secondary structure conservation between the C-terminus domain of the envelope glycoprotein of filoviruses and an immunosuppressive domain found in... |
|
|
US20130078261 |
ENVELOPED VIRUS VACCINE AND METHOD FOR PRODUCTION
The present invention provides methods of production of a purified enveloped virus antigen. In particular, it provides purified Ross River Virus (RRV) antigens, and vaccines comprising purified,... |
|
|
US20070298093 |
Synergistic Liposomal Adjuvants
The present invention relates to liposome, mixtures or liposomes and liposomal compositions comprising at least two different adjuvants and a therapeutic agent, their production and use for the... |
|
|
US20090012494 |
INTRADERMAL DELIVERY OF BIOLOGICAL AGENTS
The present invention relates to methods for intradermally delivering one or more biologically active agents such as vaccines and therapeutic agents into the dermis layer of the skin of a subject... |
|
|
US20060198854 |
Vector platforms derived from the alphavirus vaccines
Nucleic acid molecules and vector platforms derived from human virus vaccines, for example the alphavirus vaccines, including the TC-83 human vaccine, are disclosed. These vector platforms can... |
|
|
US20150150960 |
PROTECTION AGAINST DENGUE VIRUS AND PREVENTION OF SEVERE DENGUE DISEASE
The invention provides uses, methods and compositions for eliciting, stimulating, inducing, promoting, increasing, or enhancing an anti-Dengue virus T cell response in a subject. |
|
|
US20140050763 |
MODIFIED VIRAL PARTICLES WITH IMMUNOGENIC PROPERTIES AND REDUCED LIPID CONTENT USEFUL FOR TREATING AND PREVENTING INFECTIOUS DISEASES
The present invention relates to a method for reducing the occurrence and severity of infectious diseases, especially infectious diseases in which lipid-containing infectious viral organisms are... |